1-3 of 3
Francis J. Giles, M.D.
Close
Sort by
Journal Articles

The Aurora Kinase Inhibitor MLN8237 Has Potent Anticancer Activity in CML and Ph+ ALL Models and Significantly Increases the Efficacy of Nilotinib

Steffan T. Nawrocki, Ph.D., Ernest Medina, B.S., Sabrina Smith, B.S., Ronan Swords, M.D., Kevin Kelly, M.D., Swaminathan Padmanabhan, M.D., Jeffrey Ecsedy, Ph.D., Francis J Giles, M.D., Jennifer Carew, Ph.D.
Journal: Blood
Blood (2008) 112 (11): 3198.
https://doi.org/10.1182/blood.V112.11.3198.3198
Published: 2008
Journal Articles

Rapamycin Analogs Reduce mTORC2 Signaling and Inhibit AKT Activation in AML.

Zhihong Zeng, PhD, Dos D. Sarbassov, Francis J. Giles, M.D., Ismael Samudio, Ph.D., Karen W.L. Yee, C. Ellen Jackson, R.N., B.S.N., David M. Sabatini, M.D., Ph.D., Michael Andreeff, M.D., Ph.D., Marina Konopleva, M.D., Ph.D.
Journal: Blood
Blood (2006) 108 (11): 156.
https://doi.org/10.1182/blood.V108.11.156.156
Published: 2006
Journal Articles

Phase I Study Using Alternate Week Administration of the Farnesyl Transferase Inhibitor R115777 (Zarnestra™) in Patients with Myelodysplastic Syndrome.

Razelle Kurzrock, M.D., Srdan Verstovsek, M.D., John J. Wright, M.D., Susan R. Pilat, B.S.N., Jorge E. Cortes, M.D., Elihu H. Estey, M.D., Francis J. Giles, M.D., Miloslav Beran, M.D., Hagop M. Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 1436.
https://doi.org/10.1182/blood.V104.11.1436.1436
Published: 2004